Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

235 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial).
Tung N, Arun B, Hacker MR, Hofstatter E, Toppmeyer DL, Isakoff SJ, Borges V, Legare RD, Isaacs C, Wolff AC, Marcom PK, Mayer EL, Lange PB, Goss AJ, Jenkins C, Krop IE, Winer EP, Schnitt SJ, Garber JE. Tung N, et al. Among authors: krop ie. J Clin Oncol. 2020 May 10;38(14):1539-1548. doi: 10.1200/JCO.19.03292. Epub 2020 Feb 25. J Clin Oncol. 2020. PMID: 32097092 Free PMC article. Clinical Trial.
A putative role for psoriasin in breast tumor progression.
Krop I, März A, Carlsson H, Li X, Bloushtain-Qimron N, Hu M, Gelman R, Sabel MS, Schnitt S, Ramaswamy S, Kleer CG, Enerbäck C, Polyak K. Krop I, et al. Cancer Res. 2005 Dec 15;65(24):11326-34. doi: 10.1158/0008-5472.CAN-05-1523. Cancer Res. 2005. PMID: 16357139
Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
Guix M, Granja Nde M, Meszoely I, Adkins TB, Wieman BM, Frierson KE, Sanchez V, Sanders ME, Grau AM, Mayer IA, Pestano G, Shyr Y, Muthuswamy S, Calvo B, Krontiras H, Krop IE, Kelley MC, Arteaga CL. Guix M, et al. Among authors: krop ie. J Clin Oncol. 2008 Feb 20;26(6):897-906. doi: 10.1200/JCO.2007.13.5939. Epub 2008 Jan 7. J Clin Oncol. 2008. PMID: 18180460 Clinical Trial.
Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression.
Kleer CG, Bloushtain-Qimron N, Chen YH, Carrasco D, Hu M, Yao J, Kraeft SK, Collins LC, Sabel MS, Argani P, Gelman R, Schnitt SJ, Krop IE, Polyak K. Kleer CG, et al. Among authors: krop ie. Clin Cancer Res. 2008 Sep 1;14(17):5357-67. doi: 10.1158/1078-0432.CCR-08-0732. Clin Cancer Res. 2008. PMID: 18765527 Free PMC article.
A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen.
Mina L, Krop I, Zon RT, Isakoff SJ, Schneider CJ, Yu M, Johnson C, Vaughn LG, Wang Y, Hristova-Kazmierski M, Shonukan OO, Sledge GW, Miller KD. Mina L, et al. Invest New Drugs. 2009 Dec;27(6):565-70. doi: 10.1007/s10637-009-9220-1. Epub 2009 Feb 13. Invest New Drugs. 2009. PMID: 19214387 Clinical Trial.
Mechanisms of trastuzumab resistance in breast cancer.
Tolaney SM, Krop IE. Tolaney SM, et al. Among authors: krop ie. Anticancer Agents Med Chem. 2009 Mar;9(3):348-55. doi: 10.2174/1871520610909030348. Anticancer Agents Med Chem. 2009. PMID: 19275526 Review.
235 results